DIHEXA (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide / PNB-0408)
A six-amino-acid angiotensin IV analog claimed in preclinical work to be dramatically more potent than BDNF at hippocampal synaptogenesis — minimal human evidence.
At a glance
What it is: A six-amino-acid angiotensin IV analog claimed in preclinical work to be dramatically more potent than BDNF at hippocampal synaptogenesis — minimal human evidence..
Primary research applications:
- Cognitive enhancement research (preclinical)
- Hippocampal synaptogenesis / neurodegeneration model research
Editorial summary: DIHEXA is a small synthetic peptide derived from angiotensin IV that produced striking preclinical results in cell-culture and rodent models of cognition and synaptogenesis — including the often-quoted 'roughly seven orders of magnitude more potent than BDNF' claim. The clinical translation to humans has not occurred. It exists in nootropic and cognitive-enhancement communities as a research peptide rather than a validated therapeutic.
- Class / structure
- Modified hexapeptide derived from angiotensin IV (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)
- Half-life
- Reported plasma half-life of hours; CNS penetration is the more relevant pharmacology
- First described
- Developed by Joseph Harding's lab at Washington State University, late 2000s / 2010s
- Regulatory status
- Not FDA-approved; research use only
What is DIHEXA?
DIHEXA is a small modified hexapeptide derived from angiotensin IV designed to activate the HGF/c-Met (hepatocyte growth factor / Met) signaling pathway in the brain. The pathway is implicated in synaptogenesis and neuronal repair.[1]
Discovery and development
DIHEXA emerged from research at Washington State University by Joseph Harding's group on the cognitive effects of angiotensin IV and related angiotensin-derived peptides. The key 2012 paper (McCoy et al., J Pharmacol Exp Ther) reported potent procognitive and pro-synaptogenic effects in rodent models — and famously framed the potency comparison to BDNF in striking terms.
The subsequent translation pathway has been slow. M3 Biotechnology (later renamed Athira Pharma) was formed around the chemistry, but the company's most-advanced clinical program has centered on a different molecule (fosgonimeton / ATH-1017) targeting the same HGF/MET axis rather than DIHEXA itself. As of 2026, DIHEXA does not have published human clinical trial data establishing efficacy.
Mechanism of action
The proposed mechanism is augmentation of HGF/c-Met signaling at hippocampal synapses, promoting dendritic spine formation and synaptogenesis. The 2012 McCoy et al. work reported in-vitro potency that the authors framed as approximately seven orders of magnitude greater than BDNF in their assay system — a comparison that has since dominated DIHEXA discussions in nootropic communities.
Pharmacokinetics
Reported as orally bioavailable with CNS penetration in rodent models — atypical for a peptide and part of why the molecule attracted so much attention. Detailed human PK is not characterized in published trials.
What the research shows
The peer-reviewed literature on DIHEXA is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| More potent than BDNF at synaptogenesis | Specific in-vitro assay finding from 2012; specific to that experimental system | Preliminary |
| Improves cognition in humans | No published clinical trial data | Unsupported |
| Useful for treating Alzheimer's disease | The successor molecule (fosgonimeton) did not meet endpoints in Phase 2/3 ACT-AD; DIHEXA itself untested clinically | Uncertain |
| Orally bioavailable with CNS penetration | Demonstrated in rodent PK studies | Plausible |
Reported user experiences
How the research describes administration
Oral, sublingual, and topical (transdermal) protocols described in research-peptide channels; no clinical dosing standards.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
DIHEXA is a striking preclinical story whose human translation has not yet been demonstrated — and whose successor program targeting the same biology disappointed in clinical trials. The 'orders-of-magnitude more potent than BDNF' framing makes for compelling marketing copy but should be read as a specific in-vitro finding, not a clinical claim. For users encountering DIHEXA in nootropic communities, the appropriate posture is: interesting preclinical pharmacology, real but limited rodent evidence, no human clinical trials, and reasonable c-Met pathway-related long-term safety questions still open.
Frequently asked questions
Is DIHEXA really 7 orders of magnitude more potent than BDNF?
The 2012 McCoy et al. paper reported that in their specific in-vitro synaptogenesis assay, DIHEXA produced effects at concentrations approximately seven orders of magnitude lower than BDNF. That is a specific finding in a specific assay system. Whether it translates to clinically meaningful effects in humans is a separate question that hasn't been answered.
Why hasn't DIHEXA been tested in humans?
The drug development effort that grew up around DIHEXA (Athira Pharma) shifted focus to fosgonimeton (ATH-1017), a different molecule targeting the same HGF/MET biology. Fosgonimeton went into clinical trials including the Phase 2/3 ACT-AD program in Alzheimer's, which did not meet primary endpoints. DIHEXA itself remains in the preclinical research-peptide space.
Is DIHEXA safe?
The HGF/c-Met pathway is also implicated in cancer biology — chronic pharmacologic activation raises legitimate long-term safety questions that haven't been investigated in humans. Short-term tolerability appears reasonable in user reports, but those reports do not constitute systematic safety data.
References
- Wright JW, Harding JW. The brain renin-angiotensin-aldosterone system: a diversity of functions and implications for CNS diseases. Pflugers Arch. 2013;465(1):133-151. https://pubmed.ncbi.nlm.nih.gov/22538857/
- McCoy AT, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. https://pubmed.ncbi.nlm.nih.gov/23097214/
- Benoist CC, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014;351(2):390-402. https://pubmed.ncbi.nlm.nih.gov/25147406/